is semaglutide on fda shortage list not allowing compounded The FDA has removed semaglutide injection products (GLP-1) from the Hims & Hers Health stock
Description
Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis
57,58 Given the low number of FTD and LBD patients in this study, further monitoring of a possible effect of semaglutide on the risk of FTD and LBD is warranted with longer follow-up and specific populations, for example, younger populations for FTD
A company acquiring a rare disease platform needs orphan drug exclusivity confirmed in each target jurisdiction
GMP status should be verified through current supplier documentation
2025 Aug 4;390:r1606.
